Stock Analysis
Kymera Therapeutics, Inc. Common StockKYMR
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy30 analystsPrice is 68% of the way from the year's low to its high.
Cash covers 880% of debt · Q2 2026.
PMP Verdict
Weak fundamentals
Strengths
- Financial Health75
Risks
- Growth0
- Profitability0
Weak fundamentals — valuation is the only support.
Market context
-3.1% today· Z 1.0σ
Bull Case
- ✓Altman Z 44.5 — safe-zone balance sheet
What's happening with KYMR
Profile
Strong financial health; growth, profitability, moat, valuation and earnings quality lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-2.7%)0/25
- P/S (83.1x)0/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (-14.3%)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-30.8%)0/25
- ROE (-19.9%)0/25
- Net margin (-285.3%)0/25
- Operating margin (-333.5%)0/25
- Financial Health75/100 · Strong
- Altman Z (44.48)25/25
- Current ratio (10.34)25/25
- Interest coverage (-1072.5x)0/25
- Net cash / debt (Net cash)25/25
- Quality22/100 · Weak
- Piotroski F (4/9)10/25
- Beneish M (-1.94)12/25
- FCF conversion (n/a)0/25
- Margin stability (σ 200.8%)0/25
- Moat0/100 · Weak
- ROIC >12% years (0/5 yrs)0/25
- Median gross margin (-250.8%)0/25
- FCF-positive years (1/6 yrs)0/25
- Worst-year net margin (worst -794.0%)0/25
Risk Flags
- ⚠Negative FCF margin (-2.0%) — burning cash
- ⚠SBC 62.1% of revenue — real dilution cost
- ⚠6 loss-making years in recent history
- ⚠Interest coverage -1072.5× — thin debt cushion
- ⚠Revenue shrinking 14.3%/yr
About Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. Show more
It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Headquarters: WATERTOWN, MA · Employees: 273 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-2.7%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -27.1%–-2.1% · 93rd pct
P/S (TTM)83.14xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 13.7x–220.7x · 75th pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales84.9xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio5.78xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-30.8%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-19.9%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-19.5%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-285.3%D
Grade D: LowNet Income / Revenue
Operating Margin-333.5%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin-257.7%D
Grade D: LowGross Profit / Revenue
FCF Margin-200.0%D
Grade D: LowFCF / Revenue
True FCF Margin-288.7%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR-14.3%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue62.1%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score44.48A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio10.34xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio9.97xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-1072.5xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.7xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.05xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt8.80xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
22EPiotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-1.94C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability200.8%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue1.1%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.07xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Mainolfi Nello Filed | Mainolfi Nello | Option exercise | -30000 | |
Mainolfi Nello Filed | Mainolfi Nello | SellOpen market sale | -262 | |
Mainolfi Nello Filed | Mainolfi Nello | SellOpen market sale | -8230 | |
Mainolfi Nello Filed | Mainolfi Nello | SellOpen market sale | -7601 | |
Mainolfi Nello Filed | Mainolfi Nello | SellOpen market sale | -4876 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Mainolfi Nello Filed | Mainolfi Nello | SellOpen market sale | -5506 | |
Mainolfi Nello Filed | Mainolfi Nello | SellOpen market sale | -3525 | |
Mainolfi Nello Filed | Mainolfi Nello | Option exercise | +30.0K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years0/5 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)-250.8%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years1/6 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-794.0%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$8.35
Cash & short-term investments per share (Finnhub)
Book Value / Share$18.23
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$78.56M
Total debt obligations (short + long term)
Cash & Equiv.$690.99M
Cash and short-term investments
Net Debt$-612.43MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$1.51B
Shareholders' equity (book value)
Asset / Liability12.08xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$8.73B
Current Market Capitalization
Beta2.04D
Grade D: High volatilityPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Kymera Therapeutics, Inc. Common Stock (KYMR)
KYMR is down 3.11% at the last close. Piotroski F-Score of 4/9 indicates mixed fundamentals for Kymera Therapeutics, Inc. Common Stock. Altman Z-Score of 44.48 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Revenue has been contracting (CAGR ≈ -14%), which weighs on the growth outlook. Free-cash-flow margin is negative (-200%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -1072.5× leaves little room for earnings shocks.
- Kymera Therapeutics, Inc. Common Stock posted a net loss in 6 of 6 available completed fiscal years (2020–2025).
- At a valuation score of 20/100, KYMR trades at a premium to its historical multiples.
See how KYMR ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all KYMR moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 13 | After-hours | 106.68 | -4.82% | -2.05 |
| Oct 6 | Regular | 104.77 | -4.62% | -2.06 |
| Sep 23 | Regular | 115.56 | -5.33% | -3.07 |
| Sep 23 | After-hours | 115.47 | -5.40% | -3.11 |
| Sep 22 | After-hours | 122.06 | +3.73% | 2.06 |
Frequently Asked Questions about KYMR
What is the current Kymera Therapeutics, Inc. Common Stock (KYMR) stock price?
KYMR is trading at $104.78 at the last market close, down 3.11% on the session. PreMarketPrice tracks KYMR pre-market, intraday and after-hours prices.
Is KYMR stock a buy right now?
PreMarketPrice's quantitative model rates Kymera Therapeutics, Inc. Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is KYMR stock overvalued?
Kymera Therapeutics, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Kymera Therapeutics, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for KYMR. The Earnings section lists recent reports and updates as dates are announced.
What sector does Kymera Therapeutics, Inc. Common Stock operate in?
Kymera Therapeutics, Inc. Common Stock operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Kymera Therapeutics, Inc. Common Stock do?
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives.
About Kymera Therapeutics, Inc. Common Stock (KYMR) Stock
Kymera Therapeutics, Inc. Common Stock (KYMR) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Kymera Therapeutics, Inc. Common Stock is trading at $104.78, down 3.11% on the day with a market capitalization of $8.7 billion. The financial health score for KYMR is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for KYMR stock.
KYMR Stock Analysis & Key Metrics
On PreMarketPrice, you can track Kymera Therapeutics, Inc. Common Stock (KYMR) across multiple dimensions:
- Pre-market price & movement: Real-time KYMR stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for KYMR with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Kymera Therapeutics, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for KYMR.
- Sector peers: Compare KYMR against 5 other healthcare stocks on key financial metrics.
Is KYMR a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Kymera Therapeutics, Inc. Common Stock (KYMR) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Kymera Therapeutics, Inc. Common Stock (KYMR) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.